Shander Aryeh
Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, NJ 07631, USA.
Surgery. 2007 Oct;142(4 Suppl):S20-5. doi: 10.1016/j.surg.2007.06.025.
Anemia and bleeding are major sources of morbidity and mortality for a broad range of patients, and transfusion is the mainstay of treatment for the consequences of bleeding. The current literature raises, however, many questions about the independent association of poor outcome with transfusion of blood and blood products. In addition, as the availability of safe donors decreases, the costs of processing blood have escalated, mainly in response to increased demands for blood safety. New models for assessing the true costs of transfusion are discussed that allow incorporation and weighing of factors more often obscured in conventional discussions of the cost-effectiveness of transfusion.
贫血和出血是众多患者发病和死亡的主要原因,输血是治疗出血后果的主要手段。然而,当前文献提出了许多关于不良结局与输血及血液制品之间独立关联的问题。此外,随着安全供血者数量的减少,血液处理成本不断攀升,这主要是为了应对对血液安全日益增长的需求。本文讨论了评估输血真实成本的新模型,这些模型能够纳入并权衡一些在传统输血成本效益讨论中常常被忽视的因素。